Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
about
JAK2 Inhibition: Reviewing a New Therapeutical Option in Myeloproliferative NeoplasmsJanus kinase-1 and Janus kinase-2 inhibitors for treating myelofibrosisMegakaryocyte pathology and bone marrow fibrosis: the lysyl oxidase connectionCooperative epigenetic modulation by cancer amplicon genesEmerging treatment options for myelofibrosis: focus on pacritinibCirculating Cytokine Levels as Markers of Inflammation in Philadelphia Negative Myeloproliferative Neoplasms: Diagnostic and Prognostic InterestClinical potential of pacritinib in the treatment of myelofibrosisJanus kinase inhibitors: jackpot or potluck?c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated LeukemiasRandom mutagenesis reveals residues of JAK2 critical in evading inhibition by a tyrosine kinase inhibitorThe tyrphostin agent AG490 prevents and reverses type 1 diabetes in NOD miceHigh-content pSTAT3/1 imaging assays to screen for selective inhibitors of STAT3 pathway activation in head and neck cancer cell lines.EXEL-8232, a small-molecule JAK2 inhibitor, effectively treats thrombocytosis and extramedullary hematopoiesis in a murine model of myeloproliferative neoplasm induced by MPLW515L.Emerging drugs for myelofibrosis.The development, safety and efficacy of pacritinib for the treatment of myelofibrosis.AKT is a therapeutic target in myeloproliferative neoplasmsDiscovery, synthesis, and characterization of an orally bioavailable, brain penetrant inhibitor of mixed lineage kinase 3.Dual Aurora A and JAK2 kinase blockade effectively suppresses malignant transformation.Clinical proteomics of myeloid leukemia.Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes.JAK inhibitor therapy for myelofibrosis: critical assessment of value and limitations.Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).A highly sensitive quantitative real-time PCR assay for determination of mutant JAK2 exon 12 allele burdenCurrent outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.JAK2 V617F and the evolving paradigm of polycythemia vera.The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study.The stilbenoid tyrosine kinase inhibitor, G6, suppresses Jak2-V617F-mediated human pathological cell growth in vitro and in vivo.Investigational Janus kinase inhibitors.Targeting the JAK-STAT pathway in lymphoma: a focus on pacritinib.STAT3 signaling: anticancer strategies and challenges.Role and relevance of TrkB mutations and expression in non-small cell lung cancer.Chromosome 5q deletion is extremely rare in patients with myelofibrosisPhase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor.The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrowA novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2.Critical requirement for Stat5 in a mouse model of polycythemia vera.Efficacy of vorinostat in a murine model of polycythemia veraEpigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.Tyrosine 201 is required for constitutive activation of JAK2V617F and efficient induction of myeloproliferative disease in mice
P2860
Q21285040-596AF78D-4629-47E7-9FFE-FE1225BA3AA3Q24186554-95A054CC-E5ED-4D6B-A710-9D972EE4F8D0Q24607513-C520A32A-2A43-448C-9744-DE5D8556B541Q24608701-9065AE59-A4FA-4F52-B6C1-680C1C357600Q26745939-8F5D0F37-1680-466C-ACCC-FD52AEA677C9Q26777398-424D46C5-8E72-45FE-A05B-B9802AED9948Q26796450-B1CB9F71-B5E2-49E0-9D5D-10AC081432CDQ27027230-CBCF7C3F-30FB-4DCF-8EF6-E47070F4C658Q28259732-57A9CB34-1962-48D3-B67B-1D3052EC6827Q28482297-58F52981-6FD6-43BD-9B9E-FA0CBC120302Q28483660-03DD7F0A-98B1-414D-88FD-37C8FF672A17Q30408290-1173DE38-92E7-4780-976C-1E7B41711AFDQ33397674-1736E4C9-227A-4024-A689-C160589F0B31Q33404574-76BA8F90-087F-48FB-95A7-37FC75E328DBQ33435178-7E6AA45D-5E30-47ED-8ECE-7323931F5B27Q33623277-49814962-14B1-4EEC-940B-47F3BE30375FQ33654498-B715082A-F796-4920-9674-90FBA32688CDQ33917530-FA3BEA20-2EC7-47DA-82BE-A582E853064DQ33999524-5DFE8690-345F-423F-B597-465D09A24DA3Q34028255-307D917F-3D6E-40DB-A8F7-AC337FBF5C79Q34150008-C2E07CBD-EF1A-4F6B-82C6-B55158418B93Q34169114-517B88C1-D085-4997-BC9D-1C7AA45ED777Q34189794-A5FD0BD1-FF6B-40E7-8B3D-99E9CA7D8AF3Q34302770-C76CF491-5050-416C-9F0C-FDC7EB0C52BEQ34316834-4FE71BA6-0EFB-4A2A-AA85-360428C990D8Q34337681-E60CCDB6-1EF4-4974-B61F-44A3B2A1046BQ34549193-417DE06F-48A2-427B-A021-5C622154CCA1Q34575802-238A3F56-7CE4-4E0F-80F3-FA4F60F6E461Q34648724-D2CA1F31-7A55-450A-8415-80AAF43C60FBQ34648812-1B571908-5FD5-4EF1-B570-ACD170B35B0CQ34715455-B5652828-F2B4-4F8C-9C02-1CC5201ED368Q34917434-A431CB68-89F9-48E3-9BD7-5148204C4308Q35535523-DE030227-4132-4E82-87BC-935EE26FB261Q35552421-0714F454-C2BB-4907-885A-F08753429B10Q35571892-902671F2-CA48-48B2-9CBD-C0C16C57CE26Q35679582-F18EC2CF-6C66-47E0-8272-979E1B3CF05AQ35885303-F2120F6B-9F68-4E1E-84C0-D07FCA073C7BQ35909673-3D737F56-CBA7-4879-9D70-7D53AB6CBFA3Q36001930-A7927DE5-3101-4A14-8D36-1B4B394E8015Q36206435-C8832936-D656-4E82-BBC1-21351977328B
P2860
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis.
description
2009 nî lūn-bûn
@nan
2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Phase 2 study of CEP-701, an o ...... thrombocythemia myelofibrosis.
@ast
Phase 2 study of CEP-701, an o ...... thrombocythemia myelofibrosis.
@en
type
label
Phase 2 study of CEP-701, an o ...... thrombocythemia myelofibrosis.
@ast
Phase 2 study of CEP-701, an o ...... thrombocythemia myelofibrosis.
@en
prefLabel
Phase 2 study of CEP-701, an o ...... thrombocythemia myelofibrosis.
@ast
Phase 2 study of CEP-701, an o ...... thrombocythemia myelofibrosis.
@en
P2093
P2860
P50
P1433
P1476
Phase 2 study of CEP-701, an o ...... thrombocythemia myelofibrosis.
@en
P2093
Deborah A Thomas
Debra Kennedy
Fabio P S Santos
Nitin Jain
Taghi Manshouri
P2860
P304
P356
10.1182/BLOOD-2009-10-246363
P407
P577
2009-12-11T00:00:00Z